{"preliminary_commentary":{"by_channel":{"x_thread":4,"youtube":1,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"name":"Kilimanjaro","nct_id":"NCT05259839","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=kilimanjaro-nct05259839. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants with relapsed or refractory (R/R) multiple myeloma (MM) who meet the criteria outline in the protocol will receive etentamig with Pomalidomide and Dexamethasone.","label":"Part 1: Arm A (Etentamig with Pomalidomide and Dexamethasone)","type":"EXPERIMENTAL"},{"description":"Participants with R/R MM who meet the criteria outline in the protocol will receive etentamig with Lenalidomide and Dexamethasone.","label":"Part 1: Arm B (Etentamig with Lenalidomide and Dexamethasone)","type":"EXPERIMENTAL"},{"description":"Participants with R/R MM who meet the criteria outline in the protocol will receive etentamig with Daratumumab and Dexamethasone.","label":"Part 1: Arm C (Etentamig with Daratumumab and Dexamethasone)","type":"EXPERIMENTAL"},{"description":"Participants with R/R MM who meet the criteria outline in the protocol will receive etentamig with Pomalidomide and Dexamethasone, after 1-3 prior lines of therapy.","label":"Part 2: Arm E (Etentamig with Pomalidomide and Dexamethasone)","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2033-09","type":"ESTIMATED"},"conditions":["Relapsed/Refractory Multiple Myeloma"],"enrollment":{"count":283,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Etentamig","otherNames":["ABBV-383"],"type":"DRUG"},{"name":"Dexamethasone","otherNames":[],"type":"DRUG"},{"name":"Lenalidomide","otherNames":[],"type":"DRUG"},{"name":"Pomalidomide","otherNames":[],"type":"DRUG"},{"name":"Daratumumab","otherNames":[],"type":"DRUG"}],"last_update":"2026-08-14","lead_sponsor":"AbbVie","official_title":"A Dose Escalation and Expansion Study of Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Patients With Newly Diagnosed or Relapsed/Refractory Multiple Myeloma","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2033-09","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Number of Participants with Dose Limiting Toxicities (DLT) of Etentamig","timeFrame":"Up to approximately 28 Days"},{"measure":"Number of Participants with Adverse Events (AEs)","timeFrame":"Up to Approximately 3 Years"}],"references":[],"start_date":{"date":"2022-10-20","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma","url":"https://clinicaltrials.gov/study/NCT05259839"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/kilimanjaro-nct05259839"}